# US 2013/0158119 A1 · Pharmaceutical semi-solid composition of isotretinoin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158119 A1
- Document ID: US20130158119A1
- Status: Published application
- Kind: A1
- Application number: 13/525,857
- Filed: 2012-06-18
- Published: 2013-06-20
- Earliest claimed: 2000-09-22
- Assignees: Galephar Pharmaceutical Research, Inc.
- Inventors: Francis Vanderbist; Cécile Servais; Philippe Baudier
- Web page: https://patentgrep.com/patent/US20130158119A1

## CPC

- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

An oral pharmaceutical composition in the form of a capsule comprising a semisolid suspension or a solution of isotretinoin and at least a first and a second lipidic excipient, the composition exhibiting a dissolution of at least 40% within 4 hours as measured using USP paddle apparatus at 150 rpm in an aqueous dissolution medium constituted by buffer of pH 7.5, sodium lauryl sulfate 2.5% and pancreatin 1 g/L at 37° C.

### Claim 15 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the composition exhibits an isotretinoin release rate of at least 60% within 4 hours.

### Claim 16 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein isotretinoin comprises between 1% to 25% w/w of the composition, the first lipidic excipient comprises between 20% to 80% w/w of the composition and the second lipidic excipient comprises between 5% to 70% w/w of the composition.

### Claim 17 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the first lipidic excipient is selected from the group consisting of glyceroyl macrogolglycerides, polyethylene glycol esters, and mixtures thereof.

### Claim 18 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the second lipidic excipient is selected from the group consisting of vegetable oils, medium chain triglycerides, fatty acid esters, glycerol oleate and mixtures thereof.

### Claim 19 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the first lipidic excipient has a HLB value of at least 12.

### Claim 20 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the first lipidic excipient has a HLB value of at least 13.

### Claim 21 (depends on 14)

The oral pharmaceutical composition of claim 14, wherein the composition is a semi-solid suspension.

### Claim 22 (depends on 14)

The oral pharmaceutical composition of claim 14, which further comprises at least one surfactant.

### Claim 23 (depends on 22)

The oral pharmaceutical composition of claim 22, wherein the surfactant is selected from the group consisting of sorbitan fatty acid esters, polysorbate compounds, polyoxyethylene sorbitan fatty acids esters, sodium lauryl sulphate, compounds of lecithin, propylene glycol esters, fatty acid esters of propylene glycol, fatty acid esters of glycerol, mixtures thereof.

### Claim 24 (depends on 22)

The oral pharmaceutical composition of claim 22, wherein the surfactant comprises between 1% to 10% w/w of the composition.

### Claim 25 (depends on 14)

The oral pharmaceutical composition of claim 14, which further comprises at least one disintegrant.

### Claim 26 (depends on 25)

The oral pharmaceutical composition of claim 25, wherein the disintegrant is selected from the group consisting of crospovidone, sodium croscarmellose, and mixtures thereof.
